Literature DB >> 6421615

Calcium dobesilate (Doxium) as a prostaglandin synthetase inhibitor in pregnant human myometrium in vitro.

G Falkay, L Kovács.   

Abstract

This comparative study on the effect of calcium dobesilate and indomethacin on prostaglandin biosynthesis was performed on microsomal fractions of pregnant human myometrium. Both drugs inhibited prostaglandin synthesis, indomethacin being more potent. Calcium dobesilate inhibited, in a dose-dependent manner, the synthesis of 6-oxo-PGF1 alpha, PGF2 alpha, PGE2 and TXB2. Its inhibitory action is comparable to that of etamsylate.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6421615     DOI： 10.1007/bf01963593

Source DB:  PubMed          Journal:  Experientia        ISSN： 0014-4754


  3 in total

1.  Calcium dobesilate versus placebo in the treatment of diabetic retinopathy: a double-blind cross-over study.

Authors:  P G Binkhorst; O P Van Bijsterveld
Journal:  Curr Ther Res Clin Exp       Date:  1976-09

2.  Does calcium dobesilate (doxium) improve the microcirculation and the musculovenous pump in patients with varicose veins?

Authors:  J Baricevic
Journal:  Vasa       Date:  1980       Impact factor: 1.961

3.  Etamsylate as inhibitor of prostaglandin biosynthesis in pregnant human myometrium in vitro.

Authors:  L Kovács; G Falkay
Journal:  Experientia       Date:  1981-11-15
  3 in total
  3 in total

1.  Effect of calcium dobesilate on the blood-retinal barrier in early diabetic retinopathy.

Authors:  E B Leite; M C Mota; J R de Abreu; J G Cunha-Vaz
Journal:  Int Ophthalmol       Date:  1990-03       Impact factor: 2.031

Review 2.  Pathophysiological Mechanisms of Chronic Venous Disease and Implications for Venoactive Drug Therapy.

Authors:  Armando Mansilha; Joel Sousa
Journal:  Int J Mol Sci       Date:  2018-06-05       Impact factor: 5.923

Review 3.  Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids.

Authors:  Hervé Allain; Albert A Ramelet; Elisabeth Polard; Danièle Bentué-Ferrer
Journal:  Drug Saf       Date:  2004       Impact factor: 5.228
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.